Latest Regulatory Approvals News

Bindi Metals has confirmed bonanza-grade gold mineralisation at its Ravni Gold Project in Serbia, defining a 3 km high-grade corridor and preparing for maiden drilling with a preferred contractor in place.

Blue Star Helium has completed Stage 1 of its Galactica development, tying six wells into the Pinon Canyon facility and starting spot-priced helium sales. The company raised A$10 million to fund further project expansion and working capital.

Hawk Resources reports high-grade copper mineralisation at Utah's Cactus project and secures an option to acquire up to 80% of Arizona's Meerkat copper project, while progressing scandium exploration in Western Australia.

Firebird Metals has locked in a purpose-built industrial facility in Osborne Park, Perth, to house its pioneering Australian Demonstration Plant, the only fully integrated manganese concentrate-to-cathode active material facility outside China.

ReNerve Limited reports a 79% jump in quarterly sales, secures key Asia-Pacific approvals, and progresses its nerve repair pipeline with the NervAlign Nerve Guide Matrix entering Stage 3 development.

Latrobe Magnesium has achieved continuous production of high-grade Magnesium Oxide from brown coal ash and secured a US$2 million prepayment from its US offtake partner, setting the stage for magnesium metal production in the second half of 2026.

Boab Metals has secured a A$236 million syndicated loan and final regulatory approvals, accelerating construction at its Sorby Hills Silver-Lead-Zinc Project with production on track for H2 2027.

Saturn Metals has pressed forward with its Apollo Hill Gold Project, appointing Ausenco for the Definitive Feasibility Study and uncovering significant high-grade gold in the emerging Titan Zone, underpinning resource growth potential.

Finder Energy has secured A$27 million via a two-tranche placement plus a A$3 million share purchase plan to fast-track its KTJ oil project in Timor-Leste, aiming for final investment decision by mid-2026 and first oil by late 2027.

4DMedical has made significant strides in commercial adoption of its CT:VQ™ lung imaging technology, securing top US hospital contracts, regulatory approvals in Europe and the UK, and a major pharmaceutical partnership, all backed by strong capital raises and inclusion in the S&P/ASX 200.

Orthocell has initiated commercial sales of its Remplir nerve repair device in Canada, leveraging a distributor-led model to penetrate a US$75 million market and setting the stage for broader North American expansion.

Dimerix has completed adult patient recruitment in its Phase 3 ACTION3 trial for DMX-200, with a blinded review confirming the study remains statistically powered to demonstrate treatment efficacy. The company also appointed a new CFO and is negotiating up to US$50 million in non-dilutive funding.